TME Pharma
Interview with Aram Mangasarian, CEO of NOXXON, and Jamila El Bougrini, Analyst at Invest Securities discussing the company's latest data and strategy (23 June 2022)
KOL webinar with Dr. Frank A. Giordano on GLORIA study top-line results of NOX-A12 and radiotherapy combination in first-line glioblastoma (June 10, 2022)
ASCO 2022 poster presentation commented by Dr. Frank A. Giordano (June 05, 2022)
Interview with Bryan Jennings on joining NOXXON as its new CFO (November 17, 2021)
Interview with Dr. Martine Van Vugt, Senior VP Corporate Strategy and Planning at Genmab, on joining NOXXON’s Supervisory Board (June 28, 2021)
Interview with Susan Coles, General Counsel and Head of Finance at Vivet Therapeutics, on joining NOXXON’s Supervisory Board (June 28, 2021)
Interview with Gregory Weaver, CFO at atai Life Sciences, on joining NOXXON’s Supervisory Board (June 28, 2021)
Biotech Finances interview (French): Aram Mangasarian discusses NOXXON’s recent clinical results and development progress with Jacques-Bernard Taste, Editor-in-Chief at Biotech Finances, and Jean-Pierre Loza, financial analyst at Genesta (June 15, 2021)
Watch the interview of Aram Mangasarian, CEO of NOXXON Pharma, who presents the glioblastoma trial, NOXXON's clinical approach in this indication and the positive results announced on June 2, 2021
Interview with Aram Mangasarian, CEO of NOXXON, and Direct Dirgeants introducing new supervisory board candidates and goals for NOXXON in 2021 (25 May 2021)
ESMO Congress 2020 Poster Presentation by Dr. Niels Halama (Sep 2020)
Dr. Niels Halama about OPERA trial on AACR 2020
Aram Mangasarian, CEO de Noxxon, LeZoom19H BiotechFinances le 19 05 2020: Nous abordons dans cette conférence les questions d'actualité, leur impact sur l'entreprise et la vision d'Aram sur l'avenir de Noxxon, les relations avec les industriels et les investisseurs.
Aram Mangasarian Pdg Noxxon : "J'espère avoir des nouvelles intéressantes pour les investisseurs cette année". La Web TV à la rencontre des dirigeants au Biomed Event 2020
L’entretien avec Aram Mangasarian, PDG de Noxxon, dans Le journal des biotechs de Boursorama pour brosser les perspectives de la société et de ses deux produits NOX-A12 et NOX-E36.
Le PDG de NOXXON Pharma annonce le transfert de l’action vers le compartiment EURONEXT GROWTH pour être cotée en continu.
NOXXON CEO Aram Mangasarian talks to Scrip about development plans for the company's lead compound NOX-A12, which is being tested as a combination therapy for a number of cancer indications on BIO-Europe Spring 2017
We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.